Eli Lilly Alzheimer’s med donanemab likely to face UK NHS rejection
by
Contributor since / Followers
Contributor since / Followers
1 month ago
syahrir maulana/iStock via Getty Images
- The UK’s National Health Service is likely to rule Oct. 23 that Eli Lilly’s (NYSE:LLY) Alzheimer’s disease therapy donanemab, while safe, will not be approved for use due to its high cost.
- The NHS decision is expected to follow in the footsteps of one made earlier this year on Biogen’s (BIIB) lecanemab, The Telegraph reported. In August, draft guidance issued by the National Institute for Health and Care Excellence, which sets drug policy for NHS, said that treatment was too pricey to justify coverage.
- The Telegraph, just days after the lecanemab draft guidance came out, predicted that donanemab would face the same fate, citing health sources.
- In the U.S., donanemab treatment costs ~$78,000 per year when necessary scans and monitoring are factored in.